Here are the Impact of sodium-glucose cotransporter inhibitors in acute coronary syndrome patients on endothelial function and atherosclerosis related-biomarkers ATH-SGLT2i pilot study journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
Impact of sodium glucose cotransporter inhibitors in corrosion, impact of sodium glucose transport protein, impact of climate change, impact of sodium glucose cotransporter inhibitors in hemophilia, impact of sodium glucose cotransporter inhibitors in acute inflammation.
Impact of sodium-glucose cotransporter inhibitors in acute coronary syndrome patients on endothelial function and atherosclerosis related-biomarkers ATH-SGLT2i pilot study
Little is known about the effects of sodium-glucose co-transporter 2 inhibitors (SGLT2i) on atherosclerosis. We aimed to determine if a 90-day intake of Dapagliflozin could improve atherosclerosis biomarkers (namely endothelial function assessed by flow-mediated dilatation [FMD] and carotid intima-media thickness [CIMT]) in diabetic and non-diabetic acute coronary syndrome (ACS) patients when initiated in the early in-hospital phase. ATH-SGLT2i was a prospective, single-center, observational trial that included 113 SGLT2i naive patients who were admitted for ACS and who were prescribed Dapagliflozin at a fixed dose of 10 mg during their hospital stay for either type 2 diabetes or for heart failure. After 90 days of follow-up, subjects who had a continuous intake of Dapagliflozin formed the SGLT2i group, while patients who did not take Dapagliflozin formed the non-SGLT2i group. In each of these main study groups, we considered diabetic and non-diabetic subgroups. The primary e ndpoint was the difference in between baseline and 90 days in FMD (∆FMD) and in FMD rate (∆FMD%). The secondary outcome was change in CIMT (∆CIMT). We enrolled 54 patients in the SGLT2i group aged 59 ± 9 years (70.4% males) which 30 were diabetics, and 59 in the non-SGLT2i group aged 63 ± 11 years (78% males) which 34 were diabetics. After 90 days, ∆FMD and ∆ FMD% were higher in the SGLT2i group in comparison with the non-SGLT2i group (0.05 ± 0.15 vs −0.05 ± 0.11, P < .001 and 1.78 ± 3.63 vs −0.88 ± 4, P < .001). Within the SGLT2i group, the improvement of FMD% was higher in non-diabetic patients (2.85 ± 3.46 vs 0.9 ± 3.59, P = .05). Multivariate analysis showed that Dapagliflozin intake was independently associated with FMD% improvement (HR = 2.24). After 90 days, CIMT showed no significant difference between the SGLT2i and the non-SGLT2i groups. In this pilot study, a 90-day intake of Dapagliflozin at the fixed dose of 10 mg started in the acute phase of an A CS, was associated with endothelial function improvement in diabetic and non-diabetic patients. Copyright © 2024 the Author(s).
Authors : Zghal F.M.; Abbassi M.; Silini A.; Halima M.B.; Jebberi Z.; Daly F.; Ouali S.; Farhati A.; Mansour N.B.; Boudiche S.; Mourali M.S.
Source : Lippincott Williams and Wilkins
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1097/MD.0000000000040536 |
| ISSN | 00257974 |
| Volume | 103 |
You can download the article here
If You have any problem, contact us here